Share

Novartis AG - news published 359 - readings 12.827

BACK
Novartis AG

Novartis AG

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer (Form 6-K)

Novartis International AG CH-4002 Basel Switzerland http://www.novartis.com https://twitter.com/novartisnews PRESS RELEASE FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer Ad hoc announcement pursuant to Art. 53 LR • New indication approximately triples eligible patient p ...

Continue reading
28.03.2025
Novartis AG

Novartis AG

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA positive metastatic castration resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto ® to be used after one androgen receptor pathway inhibitor (ARPI) and now before chemotherapy Pluvicto significantly reduced risk of progression or death by 59% and more than doubled median radiographic progression-free survival ( rPFS) vs. change in ...

Continue reading
28.03.2025
Novartis AG

Novartis AG

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis receives third FDA approval for oral Fabhalta ® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one year with favorable safety 1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C3G 1-3 C3G is an ultra-rare kidney diseas ...

Continue reading
21.03.2025
Novartis AG

Novartis AG

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 (Form 6-K)

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 Full year • Net sales grew +12% (cc 1 , +11% USD) with core operating income 1 up +22% (cc, +19% USD) o Sales growth driven by continued strong performance from Entresto (+31% cc), Cosentyx (+25% cc), Kesimpta (+49% cc), Kisqali (+49% cc), Pluvicto (+42% cc) an ...

Continue reading
31.01.2025